Glaxosmithkline Biologicals Sa

Simone Bufali

Derek T O'Hagan

Manmohan Singh

Barbara Baudner

The invention improves TdaP vaccines by including a TLR agonist in them. This agonist can provide stronger protection, longer-lasting protection, and/or can reduce the amount of antigen which is required to achieve a particular immune response.

Adjuvanted formulations of booster vaccines

Serogroup B meningococcus antigens can successfully be combined with diphtheria, tetanus and pertussis toxoids ('DTP') to provide effective combination vaccines for protecting against multiple pathogens. These combinations are effective with a range of different adjuvants, and with both pediatric-type and booster-type DTP ratios. The adjuvant can improve the immune response which the composition elicits; alternatively, by including an adjuvant it is possible for the compositions to have a relatively lower amount of antigen while nevertheless having immunogenicity which is comparable to unadjuvanted combination vaccines.

Growing community of inventors

Siena, Italy

Simone Bufali